Pituitary adenoma pathogenesis: An update

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 4, 2012, Pages 322-327

  Rostad, Steve ^a  

^a Cellnetix Pathology and Laboratories   (United States)

Author keywords

Cell cycle; MicroRNA; Pituitary adenoma; Tumor suppressor; Tumorigenesis

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DUAL SPECIFICITY PHOSPHATASE 6; DYSKERIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYPICAN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1BETA; MICRORNA; PROTEIN KINASE B; SECURIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SMAD PROTEIN; TRANSCRIPTION FACTOR PITX2; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; WNT PROTEIN;

ALBRIGHT SYNDROME; ANEUPLOIDY; CARCINOGENESIS; CARNEY COMPLEX; CELL CYCLE; CELL CYCLE REGULATION; CELL DEATH; CELL FATE; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; EPIGENETICS; FAMILIAL CANCER; FEEDBACK SYSTEM; GENE CONTROL; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MITOSIS RATE; MULTIPLE ENDOCRINE NEOPLASIA; NONFUNCTIONING PITUITARY ADENOMA; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ADENOMA; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; ONCOGENES; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84864585261     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328354b2e2     Document Type: Review

References (47)

1. Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23:525-541.
2. Levy A. Molecular and trophic mechanisms of pituitary tumourigenesis. Horm Res Paediatr 2011; 76 (Suppl 1):2-6.
3. Yu R, Melmed S. Pathogenesis of pituitary tumors. Prog Brain Res 2010; 182:207-227.
4. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7:257-266.
5. Vandeva S, Vasilev V, Vroonen L, et al. Familial pituitary adenomas. Ann Endocrinol (Paris) 2010; 71:479-485.
6. Grossman AB. The molecular biology of pituitary tumors: a personal perspective. Pituitary 2009; 12:265-270.
7. Canaff L, Vanbellinghen JF, Kaji H, et al. Impaired transforming growth factorbeta (TGF-b) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1). J Biol Chem 2012; 287:8584-8597.
8. Farrell WE, Azevedo MF, Batista DL, et al. Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitaryadenoma. J Clin Endocrinol Metab 2011; 96:E1905-E1914.
9. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008; 93:2390-2401.
10. Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 2011; 165:509-515.
11. Vandeva S, Tichomirowa MA, Zacharieva S, et al. Genetic factors in the development of pituitary adenomas. Endocr Dev 2010; 17:121-133.
12. Raitila A, Lehtonen HJ, Arola J, et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am J Pathol 2010; 177:1969-1976.
13. Tichomirowa MA, Lee M, Barlier A, et al. Cyclin dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds. Endocr Relat Cancer 2012 (in press).
14. Xekouki P, Pacak K, Almeida M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab 2012; 97:E357-E366.
15. Xekouki P, Azevedo M, Stratakis CA. Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways. Expert Rev Endocrinol Metab 2010; 5:697-709.
16. Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol 2009; 42:75-86.
17. Yu R, Melmed S. Pituitary tumor transforming gene: an update. Front Horm Res 2004; 32:175-185.
18. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28:165-186.
19. Chen S, Xiao L, Liu Z, et al. Pituitary tumor transforming gene-1 haplotypes and risk of pituitary adenoma: a case-control study. BMC Med Genet 2011; 12:44.
20. R?́os Y, Melmed S, Lin S, Liu NA. Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet 2011; 7:e1001271.
21. Bellodi C, Krasnykh O, Haynes N, et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 2010; 70:6026-6035.
22. Dorman K, Shen Z, Yang C, et al. CtBP1 Interacts with ikaros and modulates pituitary tumor cell survival and response to hypoxia. Mol Endocrinol 2012; 26:447-457.
23. Palmieri D, Valentino T, De Martino I, et al. Pit-1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer 2011. Pit-1 overexpression enhances pituitary adenoma cell proliferation.
24. Suojun Z, Feng W, Dongsheng G, Ting L. Targeting Raf/MEK/ERK pathway in pituitary adenomas. Eur J Cancer 2012; 48:389-395.
25. Gaston-Massuet C, Andoniadou CL, Signore M, et al. Increased wingless (Wnt) signaling in pituitary progenitor/stem cells givesrise to pituitary tumors in mice and humans. Proc Natl Acad Sci U S A 2011; 108:11482-11487.
26. Zhan X, Desiderio DM. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics 2010; 3:13.
27. Formosa R, Gruppetta M, Falzon S, et al. Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol. 2012.
28. Acunzo J, Roche C, Defilles C, et al. Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells. Endocrinology 2011; 152:3884-3892.
29. Garc?́a-Fernández RA, Garc?́a-Palencia P, Sánchez MÁ , et al. Combined loss of p21(waf1/cip1) andp27(kip1) enhances tumorigenesis in mice. Lab Invest 2011; 91:1634-1642.
30. Ezzat S. Epigenetic control in pituitary tumors. Endocr J 2008; 55:951-957.
31. Michaelis KA, Knox AJ, Xu M, et al. Identification of growtharrest and DNAdamage-inducible gene b (GADD45b) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 2011; 152:3603-3613.
32. Hosoyama T, Nishijo K, Garcia MM, et al. A postnatal pax7 progenitor gives rise to pituitary adenomas. Genes Cancer 2010; 1:388-402.
33. Florio T. Adult pituitary stem cells: from pituitary plasticity to adenoma development. Neuroendocrinology 2011; 94:265-277.
34. Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest. 2011.
35. Tateno T, Asa SL, Zheng L, et al. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet 2011; 7:e1002400.
36. Roussel-Gervais A, Bilodeau S, Vallette S, et al. Cooperation between cyclin E and p27(Kip1)in pituitary tumorigenesis. Mol Endocrinol 2010; 24:1835-1845.
37. Zatelli MC, degliUberti EC. MicroRNAs and possible role in pituitary adenoma. Semin Reprod Med 2008; 26:453-460.
38. Sivapragasam M, Rotondo F, Lloyd RV, et al. MicroRNAs in the human pituitary. Endocr Pathol 2011; 22:134-143.
39. Mao ZG, He DS, Zhou J, et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol 2010; 5:79.
40. Luzi E, Brandi ML. Are microRNAs involved in the endocrine-specific patternof tumorigenesis in multiple endocrine neoplasia type 1? Endocr Pract 2011; 17 (Suppl 3):58-63.
41. Shi X, Tao B, He H, et al. MicroRNAs-basednetwork: a novel therapeutic agent in pituitary adenoma. Med Hypotheses 2012; 78:380-384.
42. Butz H, Likó I, Czirják S, et al. MicroRNA profile indicates downregulation of the TGFb pathway in sporadic nonfunctioning pituitary adenomas. Pituitary 2011; 14:112-124.
43. Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2011; pp.1-9.
44. Butz H, Likó I, Czirják S, et al. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab 2010; 95:E181-E191.
45. Cheunsuchon P, Zhou Y, Zhang X, et al. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol 2011; 179:2120-2130.
46. Shah PP, Kakar SS. Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of twist, snail, slug and E-cadherin. Cancer Lett 2011; 311:66-76.
47. Zhou W, Song Y, Xu H, et al. In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J Clin Endocrinol Metab 2011; 96:E1237-E1245